Clinical trials: Melphalan
Multiple Myeloma
A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients
The primary reason for this study is to further assess safety and efficacy data of the bortezomib/melphalan/prednisone (BMP) regimen in previously untreated and transplant ineligible multiple myeloma patients
- Trial name
- NCT00799539
- Testing
- bortezomib, melphalan, prednisone
- Where
- 3 sites in Canada
- Sponsor
- Janssen-Ortho Inc., Canada
Multiple Myeloma
Safety and Efficacy Study for the Prevention of Nausea and Vomiting in Multiple Myeloma Patients Receiving Stem Cell Transplantation.
The primary purpose of this study is to explore the efficacy of three different dose schedules of palonosetron for the prevention of emesis over a 7-day study interval in multiple myeloma patients.
- Trial name
- NCT00306735
- Testing
- Palonosetron
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eisai Inc.
Multiple Myeloma
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
The goal of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of ixazomib given as part of a combination therapy to treat subjects with relapsed (subjects whose disease came back) or…
- Trial name
- NCT02206425
- Testing
- Melphalan, Prednisone, Cyclophosphamide
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- Oncotherapeutics
Breast Cancer, Metastases
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
In metastatic breast cancer (MBC) patients who have already received anthracyclines, taxanes, antimetabolites and vinca-alkaloids and have developed drug resistance to these drugs, therapeutic options are very limited.
- Trial name
- NCT01091168
- Testing
- vinflunine, Alkylating agent of physician choice registered in cancer
- Where
- 80 sites in Argentina, Austria and 12 more
- Volunteers
- 594 people
- Sponsor
- Pierre Fabre Medicament
Multiple Myeloma
Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma
STR (Skeletal Targeted Radiotherapy, 166Ho-DOTMP) is an investigational radiopharmaceutical that delivers radiation directly to cancer cells in the bone and bone marrow.
- Trial name
- NCT00083564
- Testing
- STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)
- Where
- 21 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Poniard Pharmaceuticals
Newly Diagnosed Multiple Myeloma
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
The goal of this clinical study iMMagine-6 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus autologous stem cell transplant in participants with newly diagnosed multiple myeloma (NDMM).
- Trial name
- iMMagine-6 (NCT07903506)
- Testing
- Anitocabtagene Autoleucel, Isatuximab, Bortezomib
- Volunteers
- 750 people
- Sponsor
- Kite, A Gilead Company
Multiple Myeloma
Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM
The purpose of this study is to compare the safety and efficacy of Lenalidomide versus Placebo maintenance following melphalan, prednisone and velcade induction therapy in newly diagnosed multiple myeloma.
- Trial name
- ARUMM (NCT02112175)
- Testing
- Lenalidomide
- Where
- 73 sites in Belgium, France and 3 more
- Volunteers
- 46 people
- Sponsor
- Celgene
Multiple Myeloma
Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant
MBL deficient patients enrolled in this protocol are scheduled to be treated with melphalan-based high-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT) for their multiple myeloma.
- Trial name
- NCT00388999
- Testing
- Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Stage II Multiple Myeloma, Stage III Multiple Myeloma
Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, arsenic trioxide, and ascorbic acid, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm
- Trial name
- NCT00085345
- Testing
- arsenic trioxide, ascorbic acid, melphalan
- Where
- 19 sites in United States
- Sponsor
- Oncotherapeutics
Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the treatment.
- Trial name
- NCT05022901
- Testing
- Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Delcath Systems Inc.
Multiple Myeloma
A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)
This study will find the highest acceptable treatment dose and timing of infusion of cord blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with multiple myeloma.
- Trial name
- NCT02955550
- Testing
- rhIL-2, PNK-007
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celularity Incorporated
Multiple Myeloma
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
The purpose of this study is to determine if the addition of daratumumab to VELCADE-melphalan-prednisone (VMP) will improve very good partial response (VGPR) or better compared with VMP alone.
- Trial name
- NCT03217812
- Testing
- Velcade, Melphalan, Prednisone
- Where
- 44 sites in China, Hong Kong and 3 more
- Volunteers
- 220 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
The primary reason for this study is to determine whether the addition of VELCADE (bortezomib) for injection to standard melphalan/prednisone (MP) therapy improves the time to disease progression (TTP) in subjects with previously…
- Trial name
- NCT00111319
- Testing
- bortezomib
- Where
- United States
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00743288
- Testing
- Melphalan, Panobinostat
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
The purpose of this study is to determine if the addition of daratumumab to velcade (bortezomib) melphalan-prednisone (VMP) will prolong progression-free survival (PFS) compared with VMP alone in participants with previously…
- Trial name
- NCT02195479
- Testing
- Velcade, Melphalan, Prednisone
- Where
- 160 sites in United States, Argentina and 22 more
- Volunteers
- 706 people
- Sponsor
- Janssen Research & Development, LLC
Blood And Marrow Transplantation, Leukemia
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
The goal of this clinical research study is to learn if it is safe and feasible to transplant patients with one of two units of cord blood that has been changed in the laboratory before it is given.
- Conditions
- Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection
- Trial name
- NCT01983761
- Testing
- Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity)
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Targazyme, Inc.
Multiple Myeloma
Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
The purpose of this trial is to confirm the safety and efficacy of high-dose Melphalan HCL for Injection (Propylene Glycol-Free) as a myeloablative conditioning regimen in multiple myeloma patients (MM) undergoing autologous…
- Trial name
- NCT01660633
- Testing
- High-Dose Melphalan HCL for Injection (Propylene Glycol-Free), Autologous Transplantation
- Where
- 6 sites in United States
- Volunteers
- 61 people
- Sponsor
- Acrotech Biopharma Inc.
Multiple Myeloma
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
This study will evaluate melflufen in combination with dexamethasone in adult patients with relapsed or refractory multiple myeloma in whose disease is refractory to pomalidomide and/or an anti-CD38 monoclonal antibody.
- Trial name
- HORIZON (NCT02963493)
- Testing
- Melphalan flufenamide (Melflufen), Dexamethasone
- Where
- 20 sites in United States, France and 2 more
- Volunteers
- 157 people
- Sponsor
- Oncopeptides AB
Multiple Myeloma
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
This was a randomized, controlled, open-label, Phase 3 multicenter study which enrolled patients with RRMM following 2-4 lines of prior therapy and who were refractory to lenalidomide in the last line of therapy as demonstrated…
- Trial name
- OCEAN (NCT03151811)
- Testing
- Melflufen, Pomalidomide, Dexamethasone
- Where
- 105 sites in United States, Austria and 19 more
- Volunteers
- 495 people
- Sponsor
- Oncopeptides AB
RRMM
A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
This is a randomized, two-period, cross-over Phase 2 study, comparing PK, and assessing safety and tolerability and efficacy of peripheral and central intravenous administration of melflufen in patients with RRMM.
- Trial name
- PORT (NCT04412707)
- Testing
- Melphalan, Dexamethasone
- Where
- 10 sites in United States, Bulgaria and 3 more
- Volunteers
- 27 people
- Sponsor
- Oncopeptides AB